Cangene awarded U.K. contract to supply Vaccinia Immune Globulin
20-Sep-2005
VIG is a hyperimmune product to be used in treating and preventing a type of severe reaction that may be brought on by administration of the smallpox vaccine, and is considered to be an important component of smallpox vaccination programs. Hyperimmunes are highly purified specialty antibodies made from human plasma.
Most read news
Other news from the department business & finance
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.